Filing Details
- Accession Number:
- 0001127602-25-009691
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-17 16:33:26
- Reporting Period:
- 2025-03-17
- Filing Date:
- 2025-03-17
- Accepted Time:
- 2025-03-17 16:33:26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1061983 | Cytokinetics Inc | CYTK | Pharmaceutical Preparations (2834) | 943291317 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1852129 | Andrew Callos | 350 Oyster Point Blvd South San Francisco CA 94080 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-03-17 | 20,900 | $23.26 | 58,563 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-03-17 | 20,900 | $45.14 | 37,663 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (Right to Buy) | Disposition | 2025-03-17 | 20,900 | $0.00 | 20,900 | $23.26 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 129,000 | 2022-03-31 | 2031-03-31 | No | 4 | M | Direct |
Footnotes
- Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
Billionaire Hedge Funds
